If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-23. Numbers and descriptions here follow the published literature rather than marketing material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
One of the 4th Panzer Army commanders, Erich Hoepner, was executed for his role in the 20 July plot. Following the end of the war, one of the 4th Panzer Army former commanders, Hermann Hoth, was tried in the High Command Trial, one of the Subsequent Nuremberg Trials. Explaining his harsh measures against Jews and other civilians, he claimed that "it was a matter of common knowledge in Russia that it was the Jew in particular who participated in a very large extent in sabotage, espionage, etc." Hoth was found guilty of war crimes and crimes against humanity. On 27 October 1948, he was sentenced to 15 years in prison. In January 1951, the sentence was reviewed with no changes. Hoth was released on parole in 1954; his sentence was reduced to time served in 1957. None of the other commanders ever faced charges.
=== Pharmacodynamics === Paracetamol appears to exert its effects through two mechanisms: the inhibition of cyclooxygenase (COX) and actions of its metabolite N-arachidonoylphenolamine (AM404). Supporting the first mechanism, pharmacologically and in its side effects, paracetamol is close to classical nonsteroidal anti-inflammatory drugs (NSAIDs) that act by inhibiting COX-1 and COX-2 enzymes and especially similar to selective COX-2 inhibitors, Paracetamol inhibits prostaglandin synthesis by reducing the active form of COX-1 and COX-2 enzymes. This occurs only when the concentration of arachidonic acid and peroxides is low; under these conditions, COX-2 is the predominant form of cyclooxygenase, which explains the apparent COX-2 selectivity of paracetamol. Under typical inflammation conditions, the concentration of peroxides is high, which counteracts the reducing anti-inflammatory effect of paracetamol, rendering it negligible; in situations where peroxide levels are low, such as for COX-2 in the CNS, this inhibition and its resulting anti-inflammatory effect remain high. The second mechanism centers on the paracetamol metabolite AM404. This metabolite has been detected in the brains of animals and cerebrospinal fluid of humans taking paracetamol. It is formed in the brain from another paracetamol metabolite 4-aminophenol by action of fatty acid amide hydrolase. AM404 is a weak agonist of cannabinoid receptors CB1 and CB2, an inhibitor of endocannabinoid transporter, and a potent activator of TRPV1 receptor.
Muslim organizations in the United States were swift to condemn the attacks and called "upon Muslim Americans to come forward with their skills and resources to help alleviate the sufferings of the affected people and their families." These organizations included the Islamic Society of North America, American Muslim Alliance, American Muslim Council, Council on American-Islamic Relations, Islamic Circle of North America, and the Shari'a Scholars Association of North America. Along with monetary donations, many Islamic organizations launched blood drives and provided medical assistance, food, and shelter for victims.
During this period, the average EBITDA/sales and EBIT/sales ratios of representative companies were 15% and 71⁄2%, respectively; during the boom, they were 20% and 10–13% respectively and, during the bust, they were 10% and 5% respectively. The differences within these ranges reflects the volatility of the industry's profitability. All in all, the average Western fine-chemical firms have been making a return below the cost of capital — they are not reinvestment grade.
==== Brain ==== KORs are widely distributed throughout the brain. The claustrum represents the brain region with the highest density of KOR expression. Other CNS regions expressing moderate to high KOR densities include the prefrontal cortex, periaqueductal gray, dorsal raphe nuclei (dorsal), ventral tegmental area, substantia nigra, dorsal striatum (putamen, caudate), ventral striatum (nucleus accumbens, olfactory tubercle), amygdala, bed nucleus of the stria terminalis, hippocampus (pyramidal and molecular layers, granular cell layer of the dentate gyrus), hypothalamus, thalamus (centromedian, paraventricular, and centrolateral nuclei), locus coeruleus, spinal trigeminal nucleus, parabrachial nucleus, and solitary nucleus. Positron emission tomography (PET) imaging studies with the KOR-selective radioligand [11C]GR-103545 in non-human primates showed high binding potential (BPND > 1.3) in the pituitary gland, followed by insula, claustrum, and orbitofrontal cortex, with moderate binding (BPND 0.9–1.3) in nucleus accumbens, amygdala, and hippocampus. [3H]bremazocine binding showed elevated densities along the ventral edge of the nucleus accumbens and ventral putamen regions. There is evidence that distribution and/or function of this receptor may differ between sexes.
Sources: en.wikipedia.org
A 1984 study that combined selegiline with phenylalanine reported remarkably high effectiveness in the treatment of depression similar to that with electroconvulsive therapy (ECT). However, selegiline in its original oral form was never further developed or approved for the treatment of depression. A few years after the discovery that selegiline was a selective MAO-B inhibitor, two Parkinson's disease researchers based in Vienna, Peter Riederer and Walther Birkmayer, realized that selegiline could be useful in Parkinson's disease. One of their colleagues, Moussa B. H. Youdim, visited Knoll in Budapest and took selegiline from him to Vienna. In 1975, Birkmayer's group published the first paper on the effect of selegiline in Parkinson's disease. Speculation, by József Knoll, that selegiline could be useful as an anti-aging and pro-sexual agent, began in the 1980s. The New York Times reported that selegiline was being used non-medically as a "smart drug" by 1992. Selegiline was first introduced for clinical use in Hungary in 1977. It was approved in the oral pill form under the brand name Jumex to treat Parkinson's disease. The drug was then introduced in the United Kingdom in 1982. In 1987, Somerset Pharmaceuticals in New Jersey, which had acquired the rights to develop selegiline in the United States, filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) to market the drug for Parkinson's disease in this country. While the NDA was under review, Somerset was acquired in a joint venture by two generic drug companies, Mylan and Bolan Pharmaceuticals.
=== Risk factors === There is no known breed predilection. Approximately 88% of described cats were male; male cats also have a predisposition to diabetes mellitus. Growth hormone secreting pituitary tumours in dogs have only been observed in male dogs of large breeds. Excessive growth hormone secretion caused by progestone use has been seen in a variety of breeds of varying size, as well as in mixed breed dogs, the same is true of growth hormone excess brought on by the oestrous cycle.
In such isotopes, therefore, no neutron kinetic energy is needed, for all the necessary energy is supplied by absorption of any neutron, either of the slow or fast variety (the former are used in moderated nuclear reactors, and the latter are used in fast-neutron reactors, and in weapons). According to Younes and Loveland, "Actinides like 235U that fission easily following the absorption of a thermal (25 meV) neutron are called fissile, whereas those like 238U that do not easily fission when they absorb a thermal neutron are called fissionable."
==== Combination drugs ==== Carbidopa/entacapone/levodopa (LECIGel; LECIGon; Lecigon; Trigel) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), entacapone (catechol O-methyltransferase (COMT) inhibitor), and levodopa (dopamine precursor) [345] Levodopa/carbidopa/entacapone (ELC-200; Stalevo; Stavelo) – combination of levodopa (dopamine precursor), carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor), and entacapone (catechol O-methyltransferase (COMT) inhibitor) [346]
Estrogen from the maternal circulation is relatively ineffective, partly because of the high circulating levels of steroid-binding proteins in pregnancy. Sex steroids are not the only important influences upon hypothalamic development; in particular, pre-pubertal stress in early life (of rats) determines the capacity of the adult hypothalamus to respond to an acute stressor. Unlike gonadal steroid receptors, glucocorticoid receptors are very widespread throughout the brain; in the paraventricular nucleus, they mediate negative feedback control of CRF synthesis and secretion, but elsewhere their role is not well understood.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.